---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004644"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-19T00:20:36.172277+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FibroGen reports FY2022 revenue $140.7M, net loss $293.7M; China roxadustat sales up 74%

## Summary
- Total revenue $140.7M in 2022 vs $235.3M in 2021 (which included $120M milestone from Astellas).
- Net loss $293.7M ($3.14 per share) vs $290.0M prior year; Q4 net loss $66.2M ($0.70 per share).
- China roxadustat net product revenue $82.9M in 2022, up 74% YoY; Q4 $23.4M, up 328% YoY.
- Cash, equivalents, investments, and AR $442.7M at Dec 31, 2022; funded into 2H 2024.
- Five pivotal Phase 3 readouts expected in 2023: pamrevlumab in DMD and IPF, roxadustat in MDS and CIA.

## SEC filing metadata
- accession: 0000950170-23-004644
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/0000950170-23-004644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/fgen-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004644
- JSON: https://secwatch.observer/filing/0000950170-23-004644.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004644.txt

## Key facts
- Earnings Releases
  KYNTRA BIO, INC. reported the fourth quarter of 2022 results: revenue $34.4 million, net income $66.2 million net loss, EPS $0.70 net loss per basic and diluted share.
  - Period: the fourth quarter of 2022
  - Revenue: $34.4 million
  - Net income: $66.2 million net loss
  - EPS: $0.70 net loss per basic and diluted share
  - Result: reported results
  source text: Total revenue for the fourth quarter of 2022 was $34.4 million, as compared to $16.5 million for the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/0000950170-23-004644-index.htm
- Earnings Releases
  KYNTRA BIO, INC. reported the full year 2022 results: revenue $140.7 million, net income $293.7 million net loss, EPS $3.14 net loss per basic and diluted share.
  - Period: the full year 2022
  - Revenue: $140.7 million
  - Net income: $293.7 million net loss
  - EPS: $3.14 net loss per basic and diluted share
  - Result: reported results
  source text: Total revenue for 2022 was $140.7 million as compared to $235.3 million in 2021, which included $120 million of milestone payments from Astellas related to the EU approval of roxadustat.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/0000950170-23-004644-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.